FluMist Nasal Flu Vaccine Gets FDA Consideration for Self-Administration
XTalks
OCTOBER 25, 2023
The US Food and Drug Administration (FDA) has accepted AstraZeneca’s supplemental biologics license application (sBLA) for a self-administered option of its nasal influenza vaccine FluMist Quadrivalent. FluMist has been in the market since 2003 and is the only intranasal spray vaccine option against flu.
Let's personalize your content